Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease

Thomas Idorn, Filip K. Knop, Morten B. Jørgensen, Mikkel Christensen, Jens J. Holst, Mads Hornum, and Bo Feldt-Rasmussen

Department of Nephrology (T.I., M.B.J., M.H., B.F.-R.), Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark; Diabetes Research Division, Department of Internal Medicine (F.K.K., M.C.), Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark; and The NNF Center for Basic Metabolic Research, Department of Biomedical Sciences (F.K.K., J.J.H.), the Panum Institute, University of Copenhagen, DK-2200 Copenhagen, Denmark

Context: The affect of the kidneys in elimination and degradation of intact incretin hormones and their truncated metabolites is unclear.

Objective: To evaluate elimination and degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in patients with dialysis-dependent kidney failure.

Setting and Design: Twelve non-diabetic patients treated with chronic hemodialysis and 12 control subjects were examined in a double-blind, randomized, matched observational study at the Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark. Over 4 separate study days, synthetic human GIP or GLP-1 was infused with or without concurrent inhibition of dipeptidyl peptidase 4 using sitagliptin or placebo. Plasma concentrations of glucose, insulin, glucagon, and intact and total forms of GLP-1 or GIP were measured repeatedly. Plasma half-life (T1/2), metabolic clearance rate (MCR), area under curve, and volume of distribution for intact and metabolite levels of GLP-1 and GIP were calculated.

Results: Fasting concentrations of intact GLP-1 and GIP were increased in dialysis patients (P < .001) whereas fasting levels of GLP-1 and GIP metabolites did not differ between groups (P > .738). MCRs of intact GLP-1 and GIP, and the GLP-1 metabolite were reduced in dialysis patients on the placebo day (P < .009), and T1/2 of intact and metabolite forms of GLP-1 and GIP were comparable between groups (P > .121).

Conclusions: Unexpectedly, degradation and elimination of the intact and metabolite forms of GLP-1 and GIP seemed preserved, although reduced, in patients with dialysis-dependent kidney failure. (J Clin Endocrinol Metab 99: 2457—2466, 2014)
and regulate glucagon secretion in a glucose-dependent manner (1, 2). It is widely accepted that the intact forms of the incretin hormones, GLP-1(7–36) amide and GIP(1–42), are degraded primarily by the ubiquitous enzyme dipeptidyl peptidase 4 (DPP-4) (3–5) and to a minor extent by various neutral endopeptidases (NEPs) and additional aminopeptidases (6–8). DPP-4 cleaves off the N-terminal dipeptide of both incretin hormones yielding inactive metabolites, GIP(3–42) and GLP-1(9–36) amide, respectively. These metabolites are believed primarily to be renally cleared (3–5, 9–13), although other mechanisms may contribute, including extraction in peripheral tissues (9, 14). Only a few studies have examined the effect of impaired kidney function on elimination and degradation of the incretin hormones (10–12, 15–17). Most of these studies were performed in vitro or using animal models and most were based on assays unable to distinguish between intact hormones and metabolites. Recent studies from our group have suggested a preserved ability to eliminate GLP-1 and GIP in patients with severely reduced kidney function, although only the total forms of the incretin hormones were examined (18, 19). In the present study we determined degradation and elimination of intact forms and truncated metabolites of GLP-1 and GIP in patients with chronic dialysis-dependent, end-stage renal disease (ESRD), ie patients with no or severely reduced kidney function. We hypothesized that patients with ESRD would be characterized by severe disturbances in the metabolism of both intact and, in particular, metabolite forms of the incretin hormones, caused by reduced renal function and uremia per se.

Materials and Methods

Study protocol

The study protocol was approved by the Scientific-Ethical Committee of the Capital Region of Denmark (H-2-2009-138) and by the Danish Data Protection Agency (2007-58-0015). The study was registered with clinicaltrials.gov (NCT01391884). Written informed consent was obtained and the study was conducted according to the latest revision of the Helsinki Declaration.

Subjects

We included 12 patients with ESRD (9 Caucasians, 2 Asians, and 1 African American) and 12 control subjects with normal kidney function (all Caucasians). Patients were recruited from the hemodialysis clinic at the Department of Nephrology, Rigshospitalet, Denmark. Control subjects were recruited among participants from previous projects (18, 19). Patients were matched with the control subjects according to age, sex, and body mass index (BMI). Inclusion criteria were age 18–90 y, chronic hemodialysis treatment (for ≥3 months), and BMI 18.5–28.0 kg/m². Patients with diabetes, pancreatitis, bowel resection, inflammatory bowel disease, malignancy (previous or present), daily intake of medication known to influence glucose metabolism, or severe anemia were excluded. Control subjects met the same exclusion and inclusion criteria apart from having a normal kidney function (evaluated from plasma creatinine). Underlying renal diagnoses in the ESRD group included polycystic kidney disease (N = 3), interstitial nephritis (N = 2), hypertensive nephropathy (N = 2), hemolytic uremic syndrome (N = 1), amyloidosis (N = 1), congenital urinary tract malformation (N = 1), and unknown (N = 2). Concomitant pharmacological treatment in the ESRD group included weekly darbepoetin alfa and iron infusions (N = 12), daily use of vitamin substitutions and phosphorus binders (N = 12), pantoprazole (N = 7), furosemide (N = 4) and less frequently used agents (Supplemental Table 1). Glucose tolerance was assessed at an initial screening visit using a 2-h 75-g oral glucose tolerance test. One patient with ESRD had impaired glucose tolerance, 1 control subject had impaired fasting glucose, and all other participants had normal glucose tolerance (20). Nine patients with ESRD had well-treated mild-to-moderate hypertension (defined as use of antihypertensive agents and/or blood pressure >140/90 mm Hg at the screening visit), and one control subject had mild hypertension. Antihypertensive treatment in the ESRD group included ACE inhibitors (N = 4), angiotensin II receptor antagonists (N = 5), beta blockers (N = 3), and calcium channel blockers (N = 2). One control subject used beta blockers. Two patients with ESRD and one control subject was mildly overweight (BMI >25 kg/m²). No participants had clinically significant cardiovascular disease. Subject characteristics are presented in Table 1.

Hormone infusions, capsules, and blinding

Human GLP-1(7–36) amide and human GIP(1–42) were purchased from PolyPeptide Laboratories. The peptides were demonstrated to be greater than 97% pure and identical to the natural human peptides by HPLC, mass, and sequence analysis. The peptides were dissolved in sterilized water containing 2% human albumin (Statens Serum Institut) and subjected to duplicate sterile filtration at the Capital Region Pharmacy. Based on the molecular weights of the peptides (GLP-1(7–36) amide, 3297.67 g/mol; and GIP(1–42), 4983.68 g/mol) (21), the final GLP-1 infusion solution contained 5 µg/mL and the GIP infusion solution contained 15 µg/mL to be able to keep the weight-dependent infusions blinded. Infusion solutions were dispensed into glass ampoules and stored frozen (−20°C). The Capital Region Pharmacy also delivered blinded gelatin capsules containing 50 mg sitagliptin or placebo (placebo composed of lactose monohydrate, potato starch, gelatin, magnesium stearate, and talc). The products were delivered blinded with sealed randomization codes.

Experimental procedures

All participants went through 4 double-blinded examination days in randomized order: A) GLP-1 infusion + sitagliptin, B) GLP-1 infusion + placebo, C) GIP infusion + sitagliptin, and D) GIP infusion + placebo. One patient underwent kidney transplantation after 3 examination days and, consequently, the fourth examination day was not performed (GIP infusion + placebo). All other participants accomplished 4 examination days. A minimum of 72 h passed between the examination days and patients were free of dialysis treatment for greater than 36 hours before examination. Participants were examined after an overnight fast (10 h), and neither alcohol consumption nor vigorous...
physical activities was permitted 24 h prior to examination. A cannula was inserted into a cubital vein for hormone infusion. In control subjects, an additional iv access (for collection of blood samples from an arterio-venous fistula located at the forearm in patients with ESRD using fistula needles (gauge 17). The arm of the control subjects with the iv access for blood sampling was wrapped in a heating pad (50°C) to arterialize the blood. Each participant was permitted 24 h prior to examination. A cannula was inserted into a cubital vein for hormone infusion. In control subjects, an additional iv access (for collection of blood samples) was wrapped in a heating pad (50°C) to arterialize the blood. Each participant was permitted 24 h prior to examination. A cannula was inserted into a cubital vein for hormone infusion. In control subjects, an additional iv access (for collection of blood samples) was wrapped in a heating pad (50°C) to arterialize the blood. Each participant was permitted 24 h prior to examination.
A preceding pilot study was performed to estimate time to steady-state concentrations of intact and total forms of GLP-1 and GIP during infusion. Two patients with ESRD were examined unblinded using the same setup as described above with the exception that hormone infusions were continued until 120 min. Each patient underwent 2 examination days: GLP-1 or GIP infusion, respectively, with initial sitagliptin/placebo ingestion. Total and intact plasma concentrations of GLP-1 or GIP were measured at 17 individual time points. Using graphical evaluation, steady state was estimated to occur at 60 min for both GLP-1 and GIP. (Figures are attached as Supplemental Figure 1; only results from the main study are presented below.)

### Results

#### GLP-1

**Fasting concentrations**

Fasting concentrations of intact GLP-1 (7.1 ± 0.7 pmol/L vs. 0.8 ± 0.2 pmol/L; \( P < .0001 \)) and total GLP-1 (12.6 ± 1.2 pmol/L vs. 6.5 ± 0.8 pmol/L; \( P = .001 \)) were higher in patients with ESRD than in controls. Calculated fasting concentrations of the GLP-1 metabolite did not differ between groups (5.5 ± 1.0 pmol/L vs. 5.7 ± 0.8 pmol/L; \( P = .811 \)).

**Intact GLP-1 (GLP-1(7–36) amide)**

MCR of intact GLP-1 was reduced in patients with ESRD compared with controls on both examination days with GLP-1 infusion (\( P < .033 \)), while T1/2 was similar in the two groups (\( P > .383 \)). Baseline-corrected AUC was comparable between groups at the placebo day (\( P = .536 \)), but significantly increased in the ESRD group following GLP-1 infusion with sitagliptin (\( P = .019 \)).

**Metabolite GLP-1 (GLP-1(9–36) amide)**

MCR of the GLP-1 metabolite was significantly reduced in patients with ESRD on both examination days (\( P < .007 \)). T1/2 was increased in patients with ESRD compared with controls, insignificantly at the placebo day (\( P = .121 \)) and significantly after sitagliptin ingestion (\( P = .020 \)). AUC was significantly increased in the ESRD group at both examination days (\( P < .007 \)) and Vd was comparable between groups (\( P > .509 \)).

**Efficacy of DPP-4 inhibition**

Use of sitagliptin significantly increased T1/2 and reduced MCR of intact GLP-1 in both groups (\( P < .013 \)), whereas T1/2 and MCR of the GLP-1 metabolite remained statistically unaltered by DPP-4 inhibition (\( P > .255 \)). Curves and pharmacokinetic data are presented in Figure 1 and Table 2.

#### GIP

Due to previously described interference in the assay used for intact GIP analysis (3), baseline-subtracted GIP responses were used for evaluation of the pharmacokinetic parameters.

**Fasting concentrations**

Fasting concentrations of intact GIP (34.1 ± 2.3 pmol/L vs. 19.7 ± 1.8 pmol/L; \( P < .001 \)) and total GIP (15.2 ± 2.4 pmol/L vs. 1.7 ± 0.4 pmol/L; \( P = .001 \)) were
Increased in patients with ESRD compared with controls. A mean difference of 1.4 ± 4.1 pmol/L between groups of the calculated fasting concentrations of GIP metabolites did not differ significantly (P = .738).

Intact GIP (GIP(1–42))

MCR of intact GIP was reduced and AUC was increased in patients with ESRD compared with controls; significantly at the placebo day (P < .005) and insignificantly after sitagliptin ingestion (P > .098). T1/2 and Vd were similar in the two groups at both examination days (P > .126).

Metabolite GIP (GIP(3–42))

T1/2, MCR, and Vd of the GIP metabolite were comparable between groups during GIP infusion with sitagliptin and placebo, respectively (P > .097), whereas AUC was increased in the ESRD group at the placebo day (P = .040).

Efficacy of DPP-4 inhibition

Sitagliptin administration increased T1/2 and reduced MCR of intact GIP in both groups, although only MCR was changed with statistical significance (P < .032). Curves and pharmacokinetic data are presented in Figure 2 and Table 2.

Table 2. Pharmacokinetic Parameters for GLP-1 and GIP

| Parameter | GLP-1 + Sitagliptin | GLP-1 + Placebo |
|-----------|---------------------|----------------|
| ESRD | Control | ESRD | Control |
| Intact GLP-1 (GLP-1(7–36 amide)) | | | | |
| T1/2 (min) | 4.66 (3.84–5.92) | 4.07 (3.36–5.18) | .383 | 2.47 (1.96–3.36) | 2.53 (2.03–3.36) | .899 |
| AUC (min × pmol/L) | 867 (645–1089) | 578 (459–697) | .019 | 351 (186–516) | 301 (241–361) | .536 |
| MCR (mL/kg/min) | 36.7 (24.6–48.8) | 50.5 (44.7–56.3) | .033 | 70.5 (60.1–80.8) | 105.6 (83.1–128.2) | .005 |
| Vd (L/kg) | 0.25 (0.17–0.33) | 0.30 (0.26–0.33) | .271 | 0.25 (0.21–0.29) | 0.39 (0.30–0.47) | .004 |

Metabolite GLP-1 (GLP-1(9–36 amide)) | | | | |
| T1/2 (min) | 7.83 (5.28–15.11) | 3.26 (2.29–5.65) | .020 | 5.51 (3.99–8.91) | 3.50 (2.53–5.70) | .121 |
| AUC (min × pmol/L) | 1804 (1416–2191) | 926 (468–1385) | .004 | 2110 (1782–2439) | 1430 (944–1916) | .018 |
| MCR (mL/kg/min) | 17.5 (13.7–21.3) | 35.3 (23.2–47.4) | .007 | 13.7 (12.0–15.3) | 26.7 (19.2–34.2) | .002 |
| Vd (L/kg) | 0.20 (0.16–0.24) | 0.17 (0.11–0.22) | .509 | 0.11 (0.10–0.12) | 0.13 (0.10–0.17) | .852 |

Intact GIP (GIP(1–42)) | | | | |
| T1/2 (min) | 8.66 (5.01–31.91) | 6.30 (4.08–13.80) | .477 | 4.47 (2.86–10.21) | 3.35 (1.85–18.12) | .594 |
| AUC (min × pmol/L) | 2444 (1766–3122) | 1766 (1190–2341) | .107 | 1523 (1097–1949) | 670 (369–971) | .001 |
| MCR (mL/kg/min) | 31.8 (20.8–42.7) | 42.6 (32.5–56.6) | .098 | 49.9 (34.4–67.0) | 99.1 (67.7–136.5) | .009 |
| Vd (L/kg) | 0.40 (0.26–0.53) | 0.39 (0.30–0.51) | .921 | 0.32 (0.22–0.43) | 0.48 (0.33–0.66) | .126 |

Metabolite GIP (GIP(3–42)) | | | | |
| T1/2 (min) | 15.34 (13.26–18.18) | 10.03 (8.00–13.43) | .311 | 22.22 (16.18–35.46) | 15.77 (12.71–20.78) | .447 |
| AUC (min × pmol/L) | 1667 (860–2473) | 787 (57–1518) | .089 | 3689 (2641–4737) | 2377 (1548–3206) | .040 |
| MCR (mL/kg/min) | 27.6 (22.0–33.2) | 36.2 (26.4–45.9) | .097 | 21.6 (11.5–31.7) | 36.7 (16.6–56.8) | .163 |
| Vd (L/kg) | 0.61 (0.49–0.73) | 0.52 (0.38–0.66) | .948 | 0.69 (0.37–1.02) | 0.83 (0.38–1.29) | .346 |

Vd, volume of distribution.

Listed P values represent comparison between groups.

Footnotes represent significance levels from within-group comparisons.

a ESRD during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P < .05.

b ESRD during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P < .001.

c Controls during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P < .05.

d Controls during GLP-1/GIP infusion with sitagliptin vs. GLP-1/GIP infusion with placebo, P < .001.

Plasma glucose

No difference in fasting plasma glucose was observed between patients with ESRD and controls (5.1 ± 0.1 mmol/L vs. 5.2 ± 0.1 mmol/L; P = .476). Responses following GLP-1 and GIP infusion, respectively, with or without DPP-4 inhibition, did not differ between groups (P > .186). The glucose-lowering effect of GLP-1 and GIP infusion, respectively, was more pronounced during DPP-4 inhibition, although it did not reach statistical significance (P > .107) (Figure 3).

Insulin and glucagon

Patients with ESRD and controls exhibited comparable fasting concentrations of insulin (45.1 ± 3.8 pmol/L vs. 46.5 ± 8.6 mmol/L; P = .879), whereas fasting concentrations of glucagon were elevated in the ESRD group.
Baseline-corrected responses of insulin and glucagon were comparable between groups on all examination days ($P > 0.553$ and $P > 0.300$, respectively), with the exception that only the control group demonstrated a significant suppression of glucagon during GLP-1 infusion with sitagliptin ($P = 0.040$). The baseline-corrected insulin and glucagon responses were unaltered by pretreatment with sitagliptin compared with placebo in both groups ($P > 0.481$ and $P > 0.102$, respectively) (Figure 4).

Discussion

In the present study we demonstrate that non-diabetic patients with ESRD are characterized by A) preserved, although reduced degradation of GLP-1(7–36) amide and GIP(3–42), indicating a conserved function of DPP-4 and other peptidases involved in the truncation of intact incretin hormones; B) delayed, but relatively preserved elimination of the N-terminally truncated metabolites GLP-1(9–36) amide and GIP(3–42), pointing to the importance of concurrent nonrenal elimination of these; and C) significantly increased fasting concentrations of intact GLP-1 and GIP.

The present study examined patients with chronic dialysis-dependent ESRD, i.e., patients without or with only negligible renal function. The kidneys of patients with chronic ESRD consist of fibrotic tissue and very few, if any, functioning cells. Consequently, renal endocrine, exocrine, and tubular functions, clearance, and the ability to concentrate urine are abolished, and the renal blood flow is severely reduced or nonexistent (27–29). Eight of 12 patients in our study had no diuresis, indicating total cessation of any renal functions. Four patients had preserved diuresis in the range of 300–2300 mL/d. Urine from a patient with ESRD contains small amounts of waste products and electrolytes due to renal clearance close to 0 mL/min (30). Accordingly, the pharmacokinetic data did not differ between our ESRD subjects with and without diuresis ($P > 0.152$; MCR values for each subgroup at the placebo-days are presented as Supplemental Table 2). Thus, the present study should enable us to elaborate on the role of the kidneys in degradation and elimination of intact and metabolite forms of GLP-1 and GIP. Sitagliptin-induced DPP-4 inhibition was included in the design in order to further visualize the effect of the kidneys on the elimination of the incretin hormones after reduction of the endogenous DPP-4-mediated degradation. The placebo day allowed us to estimate the endogenous DPP-4 activity. As expected, DPP-4 inhibition resulted in increased concentrations of intact hormone levels and, hence, reduced concentrations of the metabolites compared with placebo (Figure 1, B–F and Figure 2, B–F), resulting in a significantly reduced MCR of intact GLP-1 and GIP by approximately 50% in both groups ($P < 0.014$). Thus, our data suggest preserved DPP-4-mediated degradation of intact GLP-1 and GIP in patients with ESRD. To our knowledge, only one study has previously examined degradation and elimination of intact GLP-1 and GIP in patients with renal

![Figure 2. Plasma total GIP (A and D), intact GIP (B and E), and GIP metabolite (C and F) measurements, illustrated as baseline-subtracted values during GIP infusion with dipeptidyl peptidase 4 (DPP-4) inhibition (green curves) and without DPP-4 inhibition (purple curves) in patients with ESRD (A–C) and control subjects (D–F). The gray bars indicate the time period for infusion (0–60 min). Data are mean ± SEM.](https://academic.oup.com/jcem/article-abstract/99/7/2457/2537836)
impairment: Meier et al (10) enrolled 10 patients with moderate renal impairment (creatinine clearance 46–110 mL/min) and infused GLP-1 and GIP over 30 min (ie, not sufficiently for obtaining steady state according to our pilot study (Supplemental Figure 1)). T1/2 of intact GLP-1 has previously been reported to be approximately 2 min in healthy individuals (10, 26), and Meier et al (10) found this to be insignificantly increased in patients with moderate renal impairment (3.4 min; P = .13). The same pattern was observed with regard to intact GIP, and MCR of intact GLP-1 and GIP was insignificantly reduced (3, 10). These results are in accordance with our findings, although the differences were more pronounced in patients with severe renal impairment; MCR of intact GLP-1 and GIP was reduced in the ESRD group by approximately one third compared with the control group and AUCs of both intact hormones were increased. This suggests a contributory role of the kidneys in degradation of intact GLP-1 and GIP causing reduced, although partially preserved degradation in patients with ESRD. T1/2 of intact GIP was insignificantly increased in the ESRD group, whereas T1/2 of intact GLP-1 was almost identical in the two groups. Previous studies on pigs with normal kidney function have demonstrated a renal extraction of approximately 70% of intact GLP-1 and 25% of intact GIP with glomerular filtration, proteolysis, and perhaps peritubular reuptake being involved (9, 14). With the kidneys receiving approximately 25% of the cardiac output, approximately 10–20% of the clearance of intact incretin hormones can be explained by this mechanism. In addition to DPP-4-mediated degradation of intact incretin hormones, extraction has been shown to occur in the liver (GLP-1 and GIP) (9, 14), extremities, and lungs (GLP-1) (14). These nonrenal degradation mechanisms probably explain the only slightly reduced ability to eliminate intact GLP-1 and GIP in the ESRD group as observed both with and without DPP-4 inhibition. In summary, our results suggest that nonrenal, non-DPP-4-mediated degradation constitutes a possible compensatory mechanism for the maintenance of approximately two thirds of normal degradation and elimination of the intact incretin hormones.

As with intact incretin hormones, few studies have examined elimination and degradation of the metabolites of GLP-1 and GIP in the setting of renal impairment. Most of these studies used assays unable to distinguish between intact hormones and N-terminally truncated metabolites (10–12, 15–17). Nevertheless, the kidneys have been suggested to be crucial for the elimination of “total GLP-1” (10–12) and “total GIP” (10, 15–17). Meier et al (10) measured intact and metabolite levels separately and concluded, in accordance with previous studies, that the kidneys are essential for elimination of the metabolites of GLP-1 and GIP. Nonetheless, elimination and degradation of the N-terminally truncated metabolites have never been examined in patients with ESRD. The present study clearly reveals involvement of the kidneys in elimination and degradation of the metabolites of GLP-1 and GIP. Nonetheless, elimination and degradation of the N-terminally truncated metabolites have never been examined in patients with ESRD. The present study clearly reveals involvement of the kidneys in elimination and degradation of the metabolites of GLP-1 and GIP. MCR values were reduced by 40–50% in the ESRD group compared with the control group during the placebo days and AUCs were increased. It is, however, surprising that nonrenal degradation and elimination can partly compensate for the extinct or severely reduced kidney function, which is in contrast to previous studies (10–12, 15–17). The insignificantly increased T1/2 of both metabolites in patients with ESRD and the comparable fasting concentrations between groups strengthen this conclusion. Increased activity of NEPs may constitute a possible explanation. NEP 24.11 (neprilysin, CD10) is the most commonly occurring and well studied of these enzymes and has been detected in several tissues and organs. It cleaves GLP-1 and GIP at various sites, resulting in metabolites different from the DPP-4-induced cleavage products (ie, metabolites that are not caught in the assay measuring total GLP-1 and GIP.

Figure 3. Plasma glucose responses during GLP-1 infusion (A and C) and GIP infusion (B and D) with dipeptidyl peptidase 4 (DPP-4) inhibition (black and green curves) and without DPP-4 inhibition (red and blue curves) in patients with ESRD (A and B) and control subjects (C and D). The gray bars indicate the time period for infusion (0–60 min). Data are mean ± SEM.
NEP 24.11 degrades GLP-1 both in vivo and in vitro (6, 7, 31). GIP is degraded more slowly by NEP 24.11 in vitro and its relevance in GIP metabolism in vivo has not yet been established (6, 7, 32). Organ extraction constitutes another possible compensatory mechanism for degradation and elimination of the truncated metabolites. A significant extraction from the fibrotic kidneys in patients with ESRD is unlikely (27–30) and previous studies measuring total levels of GLP-1 (14) and GIP (33) have suggested that the liver does not play a major role in the elimination and degradation of the metabolites of the incretin hormones. Both N- and C-terminal degradation of the incretin hormones occurs in peripheral tissues (9, 14), thus constituting a possible nonrenal compensatory elimination site. Extraction from other organs cannot be excluded and additional studies examining in vivo and in vitro organ-specific extraction as well as NEP activity in patients with varying degrees of renal impairment are warranted.

The presence of significantly increased fasting concentrations of intact GLP-1 and GIP in patients with ESRD represents novel findings. Causes and/or consequences cannot be extracted from the present study, but it correlates well with the results of a previous study in which patients with ESRD exhibited exaggerated postprandial responses of total GLP-1 compared with healthy control subjects (19). Furthermore, our data confirm the presence of severely increased fasting concentrations of glucagon in nondiabetic patients with ESRD (18, 19), the underlying pathophysiology of which is yet uncharted. Fasting glucose and insulin concentrations were comparable and within normal levels in both groups, suggesting preserved insulin sensitivity. Even though insulin resistance is common in patients with ESRD (34), this finding is in line with previous studies by our group (18, 19). The negligible responses of insulin and glucagon and the corresponding, limited effects on plasma glucose in the present study are probably due to the normoglycemic experimental conditions, given that neither GLP-1 nor GIP induce major changes in islet secretion at normoglycemia. Future studies using clamp techniques during GLP-1 and GIP infusion, respectively are warranted for a thorough characterization of the pancreatic effects of incretin hormones in patients with ESRD.

Safety and efficacy of incretin-based therapies in patients with impaired kidney function, including patients with ESRD (35), has been investigated in randomized controlled trials. Although our study was designed solely for pharmacokinetic analyses, our results suggest a maintained efficacy of DPP-4 in a severe uremic environment, which would be a prerequisite for use of DPP-4 inhibitors. Figure 4. Plasma insulin (A–D) and glucagon (E–H) responses during GLP-1 infusion (A, C, E, and G) and GIP infusion (B, D, F, and H) with dipeptidyl peptidase 4 (DPP-4) inhibition (black and green curves) and without DPP-4 inhibition (red and blue curves) in patients with ESRD (A, B, E, and F) and control subjects (C, D, G, and H). The gray bars indicate the time period for infusion (0–60 min). Data are mean ± SEM.
Furthermore, our data may suggest the need for dose reduction of GLP-1 receptor analogs (in case these are degraded and eliminated with similar kinetics as human GLP-1) in diabetic patients with ESRD due to reduced MCR of intact and metabolite GLP-1. The delayed metabolism of the GLP-1 metabolite in patients with ESRD may have beneficial cardiovascular effects (36), although additional studies are needed to elucidate this.

Our study has limitations. We were unable to perform a regular prestudy power analysis because no historical data on the pharmacokinetics of GLP-1 and GIP in patients with severely reduced kidney function exists. Thus, type 2 errors cannot be precluded, although the number of examined patients is above that in similar pharmacokinetic human studies. Also, the patients with ESRD comprised a heterogeneous group with different underlying renal diseases and ethnicity. To minimize confounding effects of this we matched patients and controls on age, sex, and BMI and gave preference to nondiabetic patients with ESRD with little comorbidity. We assess these minor differences to be of little significance for the pharmacokinetic evaluation of incretin hormones in patients with ESRD. The study design represents a nonphysiological setting and first-pass metabolism from the portal system is not achieved following iv infusion. This may affect the pharmacokinetic results; however, previous animal studies have not identified the liver as a major site of degradation and elimination of GLP-1 and GIP (except for hepatic DPP-4 activity). Furthermore, study conditions were identical in all participants, thus allowing comparison between groups. Blood samples were drawn from a peripheral vein in control subjects whereas an arterio-venous fistula was used in the patients with ESRD. To minimize possible differences, a heating pad was used to “arterialize” the blood in the control group. Finally, we did not measure DPP-4 activity or plasma concentrations of sitagliptin. Nevertheless, the intention of the design was, qualitatively, to examine the efficacy of DPP-4 in a uremic environment and to elucidate DPP-4-independent elimination and degradation mechanisms further. These aims were achieved.

In conclusion, our results suggest that degradation and elimination of intact and N-terminally truncated metabolites of GLP-1 and GIP, respectively, are delayed, but relatively preserved, despite an extinct or severely reduced kidney function. DPP-4-mediated degradation of the intact hormones seems unaffected by severe uremia whereas nonrenal degradation and elimination of the incretin metabolites—perhaps constituted by NEPs or yet unknown factors—seem to exist.

Acknowledgments

We are grateful to the dialysis patients and the control subjects who participated in the study. We also thank study nurse Tanja Olsen and laboratory technicians Andreas Haltorp, Lene B. Albæk and Trine H. Enevoldsen for their skillful work.

Address all correspondence and requests for reprints to: Thomas Idorn, Department of Nephrology, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. E-mail: thomas.idorn@regionh.dk.

This work was supported by unrestricted grants from the Danish Kidney Association, the Danish Society of Nephrology, the Helen and Ejnar Bjørnnow Foundation, the Erik Horslev and Wife Birgit Horslev Foundation, the A.P. Møller Foundation for the Advancement of Medical Science, the Toyota Foundation, and the Franz Hoffmann Foundation.

This study was registered in clinicaltrials.gov as trial number NCT01391884.

Disclosure Summary: The authors have nothing to disclose.

References

1. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahren B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab. 2008; 295(4):E779–E784.
2. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995; 56(2):117–126.
3. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85(10):3575–3581.
4. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinoetric polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585–3596.
5. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829–835.
6. Hupe-Sodmann K, Göke R, Göke B, et al. Endoproteolysis of glucagon-like peptide (GLP)-1 (7–36) amide by ectopeptidases in RINm5F cells. Peptides. 1997;18(5):625–632.
7. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995; 58(3):149–156.
8. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab. 2009;23(4):443–452.
9. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinoetric and antihyperglycemic effects in anesthetized pigs. Diabetes. 2001;50(7):1588–1597.
10. Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654–662.
11. Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab. 1992;74(2):379–384.

12. Ruiz-Grande C, Alarcón C, Alcantara A, et al. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res. 1993;25(12):612–616.

13. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005;128(2):117–124.

14. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271(3 Pt 1):E458–E464.

15. Jorde R, Burhol PG, Gunnes P, Schulz TB. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. Scand J Gastroenterol. 1981;16(4):469–471.

16. O’Dorisio TM, Sirinek KR, Mazzaferrri EL, Cataland S. Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism. 1977;26(6):651–656.

17. Sirinek KR, O’Dorisio TM, Gaskill HV, Levine BA. Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. Am J Surg. 1984;148(6):732–735.

18. Idorn T, Knop FK, Jørgensen M, Hornum M, Feldt-Rasmussen B. Gastrointestinal factors contribute to glucoregulatory disturbances in nondiabetic patients with end-stage renal disease. Kidney Int. 2013;83(5):915–923.

19. Idorn T, Knop FK, Jørgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Nephrol Dial Transplant. 2013;119–127.

20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553.

21. PolyPeptide Group. Catalogue. http://www.polypeptide.com/catalog/. (Accessed 9 May, 2013).

22. Orskov C, Rabenhoj I, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535–539.

23. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88(6):2706–2713.

24. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab. 2011;96(8):2519–2524.

25. Knop FK, Vilsboll T, Madshod S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 2007;50(4):797–805.

26. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220–224.

27. Heptinstall RH. 1983 End-stage kidney and the effects of dialysis. In: Heptinstall RH, ed. Pathology of the kidney. Boston: Little Brown; 617–626.

28. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1):S1–S266.

29. Takebayashi S. Sonographic evaluation of kidneys undergoing dialysis. Urol Radiol. 1985;7(2):69–74.

30. Alcazar AR. Electrolyte and acid-base balance disorders in advanced chronic kidney disease. Nefrologia. 2008;28 Suppl 3:387–93.

31. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48(9):1882–1890.

32. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36(11–12):761–765.

33. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS. The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology. 1984;115(3):1011–1018.

34. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67(2):563–568.

35. Idorn T, Knop FK, Jørgensen M, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open. 2013;3(4):e002764.

36. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–2350.